NCT00847366View on ClinicalTrials.gov

Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Non Small Cell Lung CancerSolid TumorsMetastatic Breast CancerSarcomas
Interventions
DRUG

Perifosine

All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.

DRUG

Trastuzumab

Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.

DRUG

Tamoxifen

Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .

Sponsors

Lead Sponsor

AEterna Zentaris
All Listed Sponsors
lead

AEterna Zentaris

INDUSTRY